Ann: Extension Study Begins, Analysis Suggests Survival Benefit, page-43

Thanks @Tym1ng - yeah, I get that that there is that sentence on the next slide, but my point was more than when Michael was speaking to the slide I referenced, all you heard (repeated a few times) was "Patients have been taking MPL for 16 months and are still alive, when the average life expectancy is 27 months from diagnosis". To my ears, it just sounds like only 16 months down out of 27 months - so still room for doubt.

From a promotional perspective, I would've thought a better way to say that might be "Average life expectancy is 27 months from diagnosis, yet most of the trial patients who have been taking MPL for 16 months now, have exceeded 40 months survival since initial diagnosis". You're not saying MPL is the reason for the extended duration, but I think it does sound more suggestive.

Anyway, he's the CEO and I'm sure he has his reasons. I did ask him, and he responded similar to you (see below), but I think he missed the point also about the salesmanship aspect of it.